July 8, 2020 / 8:20 AM / a month ago

BRIEF-CEPI Expands Partnership with Clover to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate

July 8 (Reuters) - Coalition For Epidemic Preparedness Innovations (CEPI):

* CEPI SAYS EXPANDS PARTNERSHIP WITH CLOVER BIOPHARMACEUTICALS TO ADVANCE DEVELOPMENT, MANUFACTURE OF COVID-19 VACCINE CANDIDATE

* COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) - TO INVEST AN ADDITIONAL $66 MILLION UPFRONT IN CLOVER’S S-TRIMER PROTEIN VACCINE CANDIDATE

* CEPI- FUNDING TO SUPPORT CLINICAL DEVELOPMENT IN PARALLEL WITH SCALE-UP OF MANUFACTURING CAPACITY TO POTENTIALLY PRODUCE 100S OF MLNS OF DOSES/YEAR

* CEPI- IF EARLY STAGE CLINICAL DEVELOPMENT OF S-TRIMER IS SUCCESSFUL, PARTNERSHIP ANTICIPATES CEPI PROVIDING SIGNIFICANT ADDITIONAL INVESTMENT Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below